Amicus Therapeutics, Inc. (DELISTED) (FOLD:DL)
14.49
0.00 (0.00%)
USD |
NASDAQ |
May 07, 16:00
Amicus Therapeutics PS Ratio : 7.087 for May 7, 2026
PS Ratio Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical PS Ratio Data
| Date | Value |
|---|---|
| May 07, 2026 | 7.087 |
| May 06, 2026 | 7.087 |
| May 05, 2026 | 7.087 |
| May 04, 2026 | 7.087 |
| May 01, 2026 | 7.087 |
| April 30, 2026 | 7.087 |
| April 29, 2026 | 7.087 |
| April 28, 2026 | 7.087 |
| April 27, 2026 | 7.087 |
| April 24, 2026 | 7.087 |
| April 23, 2026 | 7.072 |
| April 22, 2026 | 7.072 |
| April 21, 2026 | 7.072 |
| April 20, 2026 | 7.072 |
| April 17, 2026 | 7.072 |
| April 16, 2026 | 7.067 |
| April 15, 2026 | 7.072 |
| April 14, 2026 | 7.072 |
| April 13, 2026 | 7.072 |
| April 10, 2026 | 7.072 |
| April 09, 2026 | 7.077 |
| April 08, 2026 | 7.072 |
| April 07, 2026 | 7.077 |
| April 06, 2026 | 7.067 |
| April 02, 2026 | 7.062 |
| Date | Value |
|---|---|
| April 01, 2026 | 7.062 |
| March 31, 2026 | 7.072 |
| March 30, 2026 | 7.058 |
| March 27, 2026 | 7.048 |
| March 26, 2026 | 7.058 |
| March 25, 2026 | 7.058 |
| March 24, 2026 | 7.048 |
| March 23, 2026 | 7.053 |
| March 20, 2026 | 7.058 |
| March 19, 2026 | 7.033 |
| March 18, 2026 | 7.028 |
| March 17, 2026 | 7.028 |
| March 16, 2026 | 7.028 |
| March 13, 2026 | 7.028 |
| March 12, 2026 | 7.028 |
| March 11, 2026 | 7.028 |
| March 10, 2026 | 7.023 |
| March 09, 2026 | 7.028 |
| March 06, 2026 | 7.014 |
| March 05, 2026 | 7.009 |
| March 04, 2026 | 7.009 |
| March 03, 2026 | 7.014 |
| March 02, 2026 | 7.023 |
| February 27, 2026 | 7.028 |
| February 26, 2026 | 7.009 |
Price to Sales Ratio Definition
The Price to Sales Ratio (PS Ratio) is calculated by taking the stock price / revenue per share (ttm). This metric is considered a valuation metric that confirms whether the sales of a company justifies the stock price. There isn't necesarily an optimum PS ratio, since different industries will have different ranges of PS Ratios. Because of this, PS Ratio is great to evaluate from a relative standpoint with other similar companies. PS Ratio might also be a handy metric for companies that are not profitable yet, since they might be valued moreso by their overall sales and potential of becoming profitable in the future.
PS Ratio Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
PS Ratio Benchmarks
| BioMarin Pharmaceutical, Inc. | 3.684 |
| Insmed, Inc. | 23.46 |
| Ligand Pharmaceuticals, Inc. | 20.68 |
| PTC Therapeutics, Inc. | 6.167 |
| Establishment Labs Holdings, Inc. | 8.804 |
PS Ratio Related Metrics
| Price to Book Value | 16.59 |
| Price to Free Cash Flow | 150.58 |
| Price | 14.49 |
| Earnings Yield | -0.61% |
| Market Cap | 4.550B |
| Operating PE Ratio | 130.31 |